Journal of Dementia
Open Access

The Central Nervous System (CNS) is the supreme coordinator of the entire human physiology that performs multi-disciplinary tasks through a complex network. It primarily comprises of the brain and the spinal cord, wherein each of the counterpart works hand-in-hand to sustain all bodily functions. The CNS is of continued interest amongst the minds of healthcare professionals and researchers, as it still poses several puzzling challenges that are yet to be discovered.

Global central nervous system therapeutic market size was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics & therapeutics of CNS diseases are expected to escalate the treatment rate, globally. Moreover, the increasing prevalence of CNS disorders and the rising demand for effective therapeutics options are expected to boost market growth over the forecast years. Central nervous system disorders such as multiple sclerosis, epilepsy, Parkinson’s, Alzheimer's disease, and stroke have affected more than 1 billion people worldwide, as according to a report published by the WHO. The high unmet medical need has led all the major pharmaceutical companies to invest and develop novel therapies for the treatment of CNS diseases.

The annual conference of neurologists, neuroscientists and practitioners of the field of neuroscience, neurology and neurosurgery is a distinctive platform for the gathering of world- class scholars, brain researchers, public health professionals, scientists, academics, researchers from the industrial field, researchers and scientists, researchers of state of the art.

The Conference will include a range of interesting academic events, including forums, seminars, lunches for affinity groups, presentations and research lectures by renowned neurologists and neurosurgeons from around the world.

The CNS therapeutics market has experienced extensive R&D efforts in the past decade, which have resulted in introduction of novel drug-delivery systems. The advancements in drug-delivery systems are expected to enhance the adoption of a novel therapy to treat central nervous system diseases. These novel drug-delivery systems have an edge over conventional methods owing to its reduced adverse effects, ease of delivery and availability of different dosage forms. For instance, the introduction of transdermal patches for CNS disorders provides an accurate amount of medicine and relief, mostly for around 24 hours. U.S. CNS therapeutic market size, by disease, 2017-2028 (USD Billion)